PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$143.60
+2.40%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$145.61
From 52W high−9.47%
Volume245490.00
Market cap$9.29B
P/E (TTM)117.9x
P/S (TTM)33.0x
Div yield—
Key dataNov 4, 2026
Open
$145.61
From 52W high
−9.47%
Volume
245490.00
Market cap
$9.29B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
99.2x
P/E (TTM)
117.9x
RSI (14)
51.4
MomentumView details →
1D Return
+2.40%
YTD Return
+61.87%
SummaryUpdated Jun 1, 2026
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company founded in 2006 and headquartered in Newark, California. The company went public in August 2016 and specializes in discovering and developing peptide-based therapeutic drugs targeting hematology, blood disorders, and inflammatory diseases. Protagonist has evolved from a research-focused biotech startup into a company with multiple clinical-stage programs and strategic partnerships, including a significant collaboration with Janssen Biotech.
Similar companies
Latest newsMore news →
Protagonist Therapeutics President and CEO Dinesh V. Patel sold 124,000 shares of the company's common stock for approximately $18.2 million between September 8 and September 10, 2026, under a pre-arranged 10b5-1 trading plan.55d agoProtagonist Therapeutics announced a share repurchase program authorizing up to $300 million of its common stock, funded from cash and collaboration payments.57d ago